Literature DB >> 22500622

Fragile X syndrome therapeutics S(C)TEP through the developmental window.

Aditi Bhattacharya1, Eric Klann.   

Abstract

Treatment for fragile X syndrome and related autism spectrum disorders has long been thought to be effective only during a narrow window early in development. In this issue of Neuron, Michalon et al. (2012) dispel this myth.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22500622     DOI： 10.1016/j.neuron.2012.03.014

Source DB:  PubMed          Journal:  Neuron        ISSN： 0896-6273            Impact factor:   17.173


  4 in total

1.  Ube3a reinstatement identifies distinct developmental windows in a murine Angelman syndrome model.

Authors:  Sara Silva-Santos; Geeske M van Woerden; Caroline F Bruinsma; Edwin Mientjes; Mehrnoush Aghadavoud Jolfaei; Ben Distel; Steven A Kushner; Ype Elgersma
Journal:  J Clin Invest       Date:  2015-04-13       Impact factor: 14.808

2.  Glycogen synthase kinase-3 inhibitors reverse deficits in long-term potentiation and cognition in fragile X mice.

Authors:  Aimee V Franklin; Margaret K King; Valle Palomo; Ana Martinez; Lori L McMahon; Richard S Jope
Journal:  Biol Psychiatry       Date:  2013-09-13       Impact factor: 13.382

3.  Reducing eIF4E-eIF4G interactions restores the balance between protein synthesis and actin dynamics in fragile X syndrome model mice.

Authors:  Emanuela Santini; Thu N Huynh; Francesco Longo; So Yeon Koo; Edward Mojica; Laura D'Andrea; Claudia Bagni; Eric Klann
Journal:  Sci Signal       Date:  2017-11-07       Impact factor: 8.192

4.  Lithium treatment alleviates impaired cognition in a mouse model of fragile X syndrome.

Authors:  M K King; R S Jope
Journal:  Genes Brain Behav       Date:  2013-08-29       Impact factor: 3.449
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.